Novavax to Participate in the Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 05 September 2017 10:05

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE)

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the

Error. Page cannot be displayed. Please contact your service provider for more details. (1)

Company will participate in Citi’s 12th Annual Biotech Conference.

Conference details are as follows:

Date: Thursday, September 7, 2017
Location: Mandarin Oriental hotel, Boston, MA

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:   Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Director, Investor Relations ir@novavax.com 240-268-2000  Westwicke Partners John Woolford john.woolford@westwicke.com 443-213-0506  Media Russo Partners, LLC David Schull Maggie Beller david.schull@russopartnersllc.com maggie.beller@russopartnersllc.com 212-845-4271

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BMR:1